RSL-3

SKU: orb1226767

Description

An oncogenic RAS-selective lethal compound that actvates iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells, inhibits glutathione peroxidase (GPX4) and induces ferroptosis in BJeLR cells (EC50=10 nM); increases PTGS2 expression and significantly inhibits tumor growth in a xenograft mouse model (100 mg/kg).(In Vitro):RSL3 (0-8 μM, 72 hours) potently reduces the viability of HN3 cells, with IC50s of 0.48 μM in HN3 and 5.8 μM in HN3-rslR cells, respectively.RSL3 (0-8 μM, 24 hours) reduces the expression of GPX4 protein, increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.(In Vivo):RSL3 (100 mg/kg, Intratumorally twice per week for 20 days) significantly inhibits the growth of tumor in combination with trigonelline in mice bearing HN3R cells.

Key Properties

• CAS Number: 1219810-16-8
• MW: 440.8763
• Purity: >98% (HPLC)
• Formula: C₂₃H₂₁ClN₂O₅
• SMILES: O=C(OC)[C@@H]1N(C(CCl)=O)[C@@H](C2=CC=C(C(OC)=O)C=C2)C3=C(C(C=CC=C4)=C4N3)C1
• Target: Ferroptosis
• Solubility: DMSO: ≥ 31 mg/mL

Bioactivity

• In Vivo:
  Animal model: Ten-week-old athymic BALB/c male nude mice (nu/nu) bearing HN3R cells. Dosage: 100 mg/kg in combination with trigonelline (50 mg/kg). Administration: Intratumorally twice per week for 20 days. Result: Significantly reduced the volume of tumor combined with trigonelline in mice.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RSL3 | 1S,3R-RSL3

Quick Database Links

Gene Symbol

Ferroptosis